Rivaroxaban
Transient Ischemic Attack
General Hospital of Shenyang Military RegionSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Transient Ischemic Attack cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin Sichuan Provincial People's Hospital | Phase 4 | BBB |
CLOPIDOGREL Sichuan Provincial People's Hospital | Phase 4 | BBB |
Ticagrelor Mazandaran University of Medical Sciences | Phase 3 | BBB |
Cilostazol Stanford University | Phase 4 | BBB |
Apixaban Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Phase 4 | BBB |
View all 42 →
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →